← ANALYST RATINGS · TIPRANKS
Penumbra (PEN): analyst forecast and price target
Analyst consensus
Hold0 Buy2 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $374, the highest $374, the lowest $374. The average is +16.6% from the last price of $321.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $350 | Hold | +9.1% | Reiterated | 05.10.26on TipRanks 07:21 | −0.8%next day −0.6% · 5 days +0.8% | ↗ |
| Name not given | — | $374 | Hold | +16.6% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −0.3%next day −0.9% · 5 days −1.5% | ↗ |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $378 → $362−4.2% | Buy | +12.8% | Reiterated | 30.08.26on TipRanks 00:05 | — | |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $374 | Hold | +16.6% | Reiterated | 04.08.26on TipRanks 07:51 | −1.4%next day −0.1% · 5 days +0.7% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $374 | Hold | +16.6% | Reiterated | 03.08.26on TipRanks 07:21 | −0.9%next day −1.4% · 5 days −1.1% | ↗ |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $358 → $363+1.4% | Buy | +13.1% | Reiterated | 31.07.26on TipRanks 10:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $349 → $358+2.6% | Buy | +11.6% | Reiterated | 31.07.26on TipRanks 10:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $336 → $344+2.4% | Hold | +7.2% | Reiterated | 31.07.26on TipRanks 10:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $346 → $360+4.0% | Buy | +12.2% | Upgrade | 31.07.26on TipRanks 10:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $347 → $352+1.4% | Buy | +9.7% | Upgrade | 31.07.26on TipRanks 10:05 | — | |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | — | Hold | — | Reiterated | 10.07.26on TipRanks Jul 14 07:20 | −0.4%next day +1.0% · 5 days +1.6% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $335 → $320−4.5% | Buy | −0.3% | Reiterated | 06.07.26on TipRanks 08:55 | −1.0%next day +0.5% · 5 days +0.5% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | — | Hold | — | Reiterated | 25.02.26on TipRanks 14:45 | −1.1%next day +1.5% · 5 days +1.4% | ↗ |
| Priya Sachdeva★★★★★★★★★★#3757 · hits 73% · avg +21.3% | UBS | $335 → $374+11.6% | Hold | +16.6% | Downgrade | 20.01.26on TipRanks 09:45 | +3.4%next day −0.5% · 5 days −1.5% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Hold | — | Downgrade | 17.01.26on TipRanks Jan 15 09:40 | +11.6%next day +0.2% · 5 days +2.9% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $370 → $374+1.1% | Hold | +16.6% | Downgrade | 16.01.26on TipRanks 05:10 | +0.2%next day +3.4% · 5 days +2.2% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $345 → $374+8.4% | Hold | +16.6% | Downgrade | 15.01.26on TipRanks Jan 16 05:18 | +11.6%next day +0.2% · 5 days +2.9% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $374 | Hold | +16.6% | Downgrade | 15.01.26on TipRanks 20:20 | +0.2%next day +3.4% · 5 days +2.2% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | — | Buy | — | Reiterated | 15.01.26on TipRanks 09:45 | +11.6%next day +0.2% · 5 days +2.9% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $330 → $374+13.3% | Hold | +16.6% | Downgrade | 15.01.26on TipRanks 09:40 | +11.6%next day +0.2% · 5 days +2.9% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $275 → $370+34.5% | Buy | +15.3% | Upgrade | 18.12.25on TipRanks 05:05 | +1.2%next day −0.7% · 5 days −1.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Penumbra
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $368 at a price of $318 (+15.9%); now: $368 at $321 (+14.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 1 | 1 | 0 |
| Hold | 0 | 2 | 2 | 4 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.20 (from $1.07 to $1.38). Last quarter: $0.88.
Sales
Next quarter’s sales estimate — $401M (from $398M to $406M). Last quarter: $390M.
Best top-analyst consensus in the sector · Healthcare
About Penumbra
- CEO: Adam Elsesser
- Employees: 4,700
- One Penumbra Place, Alameda, CA, 94502, US
- www.penumbrainc.com
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗